Patents by Inventor Yoko Takahashi

Yoko Takahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10369659
    Abstract: A hexagonal single crystal wafer is produced from a hexagonal single crystal ingot. The wafer producing method includes a separation start point forming step of setting the focal point of a laser beam having a transmission wavelength to the ingot inside the ingot at a predetermined depth from the upper surface of the ingot. The separation start point forming step includes a first step of forming the separation start point with a first power and a second step of setting the focal point at the modified layer previously formed in the first step and then applying the laser beam to the ingot with a second power higher than the first power at an increased repetition frequency in the condition where the energy per pulse of the laser beam is the same as that in the first step, thereby separating the cracks from the modified layer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 6, 2019
    Assignee: DISCO CORPORATION
    Inventors: Kazuya Hirata, Yoko Nishino, Kunimitsu Takahashi
  • Publication number: 20190217487
    Abstract: According to one embodiment, a gripping tool includes a gripper. The gripper is flexible. A granular material is provided in an interior of the gripper. The gripping tool grips a workpiece by depressurizing the interior of the gripper in a state in which the gripper is caused to contact the workpiece. At least a portion of the gripper includes a resin member and a fibrous member. The fibrous member is provided inside the resin member.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 18, 2019
    Applicant: KABUSHIKI KAISHA TOSHIBA
    Inventors: Hiromasa TAKAHASHI, Yoko TOKUNO, Emiko ISHIDA
  • Publication number: 20190217486
    Abstract: According to one embodiment, a gripping tool includes a gripper. The gripper is flexible. A granular material is provided in an interior of the gripper. The gripping tool grips a workpiece by depressurizing the interior of the gripper in a state in which the gripper is caused to contact the workpiece. The gripper includes a first portion contacting the workpiece, a second portion opposing the first portion, and a fibrous membrane having a plurality of pores and being provided between the first portion and the second portion. A diameter of at least a portion of the pores is smaller than a diameter of the granular material. The granular material is provided between the fibrous membrane and the second portion.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 18, 2019
    Applicant: KABUSHIKI KAISHA TOSHIBA
    Inventors: Hiromasa TAKAHASHI, Yoko Tokuno, Kenta Fukatsu, Emiko Ishida
  • Publication number: 20190084938
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
  • Patent number: 10202627
    Abstract: An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 12, 2019
    Assignees: The Kitasato Institute, Nagase & Co., Ltd.
    Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Yuki Inahashi
  • Patent number: 10183913
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: January 22, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Patent number: 10087146
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 2, 2018
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Publication number: 20180273489
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
  • Publication number: 20170306371
    Abstract: An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.
    Type: Application
    Filed: February 28, 2017
    Publication date: October 26, 2017
    Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Yuki Inahashi
  • Publication number: 20170217902
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2 , R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 3, 2017
    Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
  • Patent number: 9663472
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: May 30, 2017
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Patent number: 9457102
    Abstract: To provide a technology for introducing a PMO with remarkably enhanced cell permeability, leading to significantly enhanced introduction efficiency to thereby provide a therapeutic drug that dramatically ameliorates a medical condition of DMD. Also provided is a therapeutic drug for Duchenne muscular dystrophy, including as an active ingredient a Bubble liposome having a specific morpholino oligomer (PMO) bound to a surface thereof, in which the PMO is introduced into a muscle fiber (muscle cell) of a muscle tissue with high efficiency by administration of the therapeutic drug into the muscle tissue or into a blood vessel followed by ultrasound irradiation to the muscle tissue transcutaneously.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: October 4, 2016
    Assignee: NEPA GENE CO., LTD.
    Inventors: Yoichi Negishi, Yoko Takahashi, Kazuo Maruyama, Yukihiko Aramaki
  • Patent number: 9000194
    Abstract: The present invention addresses the problem of providing an anti-trypanosomal drug having a novel skeleton, in order to solve issues that occur with conventional technologies. The present invention is based on the discovery of a microbe that produces an anti-trypanosomal drug having a novel skeleton. Specifically, this invention provides: a compound indicated by formula (I) having a trypanosomal inhibitory activity; an analog thereof; a production method therefor; and a Lechevalieria sp. K10-0216 strain that produces said compound.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 7, 2015
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Kazuhiko Otoguro, Kazuro Shiomi, Masato Iwatsuki, Atsuko Matsumoto
  • Publication number: 20140315971
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: July 7, 2014
    Publication date: October 23, 2014
    Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
  • Patent number: 8809383
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 19, 2014
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Publication number: 20140206889
    Abstract: [Problem] The present invention addresses the problem of providing an anti-trypanosomal drug having a novel skeleton, in order to solve issues that occur with conventional technologies. [Solution] The present invention is based on the discovery of a microbe that produces an anti-trypanosomal drug having a novel skeleton. Specifically, this invention provides: a compound indicated by formula (I) having a trypanosomal inhibitory activity; an analog thereof; a production method therefor; and a Lechevalieria sp. Kl0-0216 strain that produces said compound.
    Type: Application
    Filed: August 31, 2012
    Publication date: July 24, 2014
    Applicant: THE KITASATO INSTITUTE
    Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Kazuhiko Otoguro, Kazuro Shiomi, Masato Iwatsuki, Atsuko Matsumoto
  • Publication number: 20140155813
    Abstract: To provide a technology for introducing a PMO with remarkably enhanced cell permeability, leading to significantly enhanced introduction efficiency to thereby provide a therapeutic drug that dramatically ameliorates a medical condition of DMD. Also provided is a therapeutic drug for Duchenne muscular dystrophy, including as an active ingredient a Bubble liposome having a specific morpholino oligomer (PMO) bound to a surface thereof, in which the PMO is introduced into a muscle fiber (muscle cell) of a muscle tissue with high efficiency by administration of the therapeutic drug into the muscle tissue or into a blood vessel followed by ultrasound irradiation to the muscle tissue transcutaneously.
    Type: Application
    Filed: April 25, 2012
    Publication date: June 5, 2014
    Applicant: NEPA GENE CO., LTD.
    Inventors: Yoichi Negishi, Yoko Takahashi, Kazuo Maruyama, Yukihiko Aramaki
  • Publication number: 20140031406
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
  • Patent number: 8569353
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: October 29, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Publication number: 20130116296
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Application
    Filed: July 14, 2011
    Publication date: May 9, 2013
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi